Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Woeltje et al., 1990a
With further in-depth analysis of its regulatory network and continued optimization of activator design, SIRT1 holds significant potential as a breakthrough target for multi-pathway, systemic, and precise intervention in MASLD
So these are really key fundamentals
Common Side Effects: Injection site reactions (erythema, pruritus, pain) Arthralgia (joint pain) Peripheral edema (fluid retention) Myalgia (muscle pain) Pain in extremities Important Warnings: Contraindicated in active malignancy: GH/IGF-1 promote cell proliferation Contraindicated in pregnancy: Category X Glucose monitoring required: May affect glucose metabolism IGF-1 monitoring recommended: To assess response and safety Rare but Serious: Potential tumor growth stimulation Glucose intolerance/diabetes exacerbation Hypersensitivity reactions Fluid retention complications Regulatory Status United States: FDA approved (2010) for HIV-associated lipodystrophy
Marrink, S
US$ 29.32
US$ 28.70
US$ 25.75
US$ 22.18
US$ 22.23